Fig. 1

FGF19^ΔKLB retains BA-regulatory activity in vitro and in vivo. (A-D) Effects of FGF19^WT and FGF19^ΔKLB on the Cyp7a1(A), Cyp8b1(B), Cyp27a1(C), and Cyp7b1(D) levels in HepG2 cell. Expression of Cyp7a1, Cyp8b1, Cyp27a1, and Cyp7b1 levels were determined by RT-PCR and relative to β-actin (n = 4). (E-H) The effects of FGF19^WT and FGF19^ΔKLB on the hepatic Cyp7a1(E), Cyp8b1(F), Cyp27a1(G) and Cyp7b1(H) mRNA levels. Injections of recombinant FGF19^WT and FGF19^ΔKLB into the abdominal cavity of 12-week-old C57BL/6J mice revealed differences between the two proteins (n = 10 mice per group). RT-PCR was used to measure hepatic mRNA levels, and the results were standardized to β-actin mRNA. Mean ± SEM was chosen to represent the data; *p < 0.05, **p < 0.01, ****p < 0.0001; ns, not significant; (A-H) conventional one-way ANOVA, then Tukey (n = 4 or 10)